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Here we show that pemetrexed-treated mesothelioma cells
undergo accelerated senescence. This is characterized by
the secretion of proinﬂammatory and mitogenic cytokines,
reminiscent of an SASP (senescence-associated secretory
phenotype). Conditioned media from senescent MPM
(malignant pleural mesothelioma) cells trigger the emer-
gence of EMT (epithelial-to-mesenchymal)-like, clono-
genic and chemoresistant cell subpopulations, expressing
high levels of ALDH (aldehyde dehydrogenase) activity
(ALDHbright cells). We show by ﬂuorescence-activated cell
sorting of puriﬁed ALDHbright and ALDHlow cells, that
both cell-autonomous and cell-non-autonomous mechan-
isms converge to maintain the SASP-induced, EMT-like
cell subpopulations. Chemoresistant ALDHbright cells exist
within primary MPM specimens and enrichment for
ALDHbright cells correlates with an earlier tumor onset
into NOD/SCID mice. We show that RASv12 expression
induces SASP-like changes in untransformed human
mesothelial cells, and that p53 ablation increases the
effect of RASv12 expression. We identify STAT3 activa-
tion as a crucial event downstream to SASP signaling. In
fact, small hairpin RNA-mediated ablation of STAT3
deeply attenuates the induction of EMT genes and the
increase of ALDHbright cells induced by SASP-cytokines.
This strongly affects the chemoresistance of MPM cells
in vitro and leads to anticancer effects in vivo.
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Introduction
In addition to its role in tumor suppression, cellular
senescence is increasingly recognized as an active
program of cell stress response characterized by distinct
epigenetic and metabolic changes and by broad effector
mechanisms, such as DNA damage response (Campisi,
2001; Ben-Porath and Weinberg, 2004). In addition,
genotoxic stress and oncogene expression promote a
complex senescence leading to the secretion of cytokines
and pro-mitogenic factors, named SASP (senescence-
associated secretory phenotype; Rodier et al., 2005;
Young and Narita, 2009; Coppe et al., 2010; Laberge
et al., 2011). SASP-induced chemokines are known to
induce EMT (epithelial-to-mesenchymal)-like changes in
neighboring cell populations, and this may be consid-
ered as a mechanism of tumor progression (Laberge
et al., 2011). However, it is not entirely clear whether
SASP signaling can impinge on the progression of the
neoplastic disease by modulating chemoresistance and
tumor-initiating-activity. Here we aim to investigate this
by using malignant pleural mesothelioma (MPM) as an
experimental model. MPM can be an appropriate model
for this study for several reasons. First, MPM is
characterized by an extraordinary resistance to com-
monly used chemotherapeutic agents, such as peme-
trexed and cisplatin, whose administration increases
survival of patients of only few months (Hazarika et al.,
2005). Indeed, a large fraction of short-term primary
cultures from mesothelioma patients exhibits intermedi-
ate-to-extreme drug resistance in vitro (Mujoomdar
et al., 2010). Second, recent evidence show that
upregulation of senescence markers in MPM patients
undergone platinum-based therapy is associated with a
worse prognosis (Sidi et al., 2011). Third, SASP-induced
cytokines are known to be autocrine and paracrine
growth- and invasion-promoting signaling molecules for
malignant mesothelioma in vitro and in vivo (Fujino
et al., 1996; Galffy et al., 1999; Albonici et al., 2009;
Hillegass et al., 2010). In the present work, we show that
both pemetrexed treatment and RASv12 expression
trigger SASP-like changes in transformed and untrans-
formed mesothelial cells. This stimulates the emergence
of chemoresistant cell subpopulations with features of
mesenchymal, tumor-initiating cells. We show that both
cell-autonomous and cell-non-autonomous mechanisms
maintain the SASP-induced EMT-like cell subpopula-
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tions. Chemoresistant ALDH (aldehyde dehydrogen-
ase)bright cells exist within primary MPM specimens, and
enrichment for ALDHbright cells correlates with an earlier
tumor onset in NOD/SCID mice. Finally, we identify
STAT3 activation as a crucial event downstream to
SASP signaling. shRNA-mediated STAT3 ablation
affects the number of ALDHbright cells and the chemore-
sistance of MPM cells in vitro and in vivo.
Results
MPM cell lines contain clonogenic chemoresistant cell
subpopulations
We evaluated the viability of multiple MPM cell lines
(and of a primary, untransformed human mesothelial
cell line, (HMC) treated with pemetrexed (0–80 mM,
72 h). We observed a dramatic drop in cell viability of
HMC cells, while a signiﬁcant fraction of MPM cells
survived the treatment even at high doses of pemetrexed
(Figure 1a). Drug-response assay performed with
surviving (replated) MPM cells conﬁrmed a relative
increase of chemoresistant cells, as shown by increased
CC50 (cytotoxic concentration, the concentration that
reduces cell viability by 50%) values (Supplementary
Figures 1A and B). Clonogenic assays with either short-
term-treated (5–50 mM, 6-h pulse, Figure 1b, upper
panel) or chronically treated MSTO211H cells (5–
50 mM, 96-h pulse, Figure 1b, lower panel) revealed that
prolonged treatment with pemetrexed selected for highly
clonogenic cells (Figure 1b, lower panel). Interestingly,
pemetrexed treatment (10 mM, 96 h) concomitantly trig-
gered cell senescence in a signiﬁcant fraction of the
MPM cells (60%), as assessed by the positivity of the
treated cells for senescence-associated b-galactosidase
(SA-b-Gal) staining (Figures 1c and d, left), by the drop
in 50-bromo-20-deoxyuridine (BrdU) incorporation
(Figure 1d, middle) and by the increased levels of p21
mRNA (Figure 1d, right).
Senescent MPM cells secrete cytokines and pro-mitogenic
factors
The coexistence of both senescent and clonogenic cells
within the pemetrexed-treated MPM cells suggest that
paracrine factors produced by senescent MPM cells
could modulate the behavior of the neighboring cell
subpopulations, according to a SASP model (Coppe
et al., 2010). Quantitative PCR (Q–PCR) revealed that
pemetrexed (and not vehicle)-treated MSTO211H cells
showed upregulation of IL6, IL8, VEGF-A and of
IFNg, CXCL1 and PlGF1 mRNAs (Figure 1e), which
paired with the increased secretion of the mentioned
factors in the conditioned medium (CM) (Figure 1f).
This response was a feature of other pemetrexed-treated
MPM cell lines (Supplementary Figure 2A).
CM derived from senescent MPM cells triggers EMT
features in vitro and in vivo
We tested the effect of CM from pemetrexed-treated
(p-CM), senescent MSTO211H cells on their untreated
counterparts (as compared with CM from vehicle-
treated cells (v-CM)). We found that p-CM (and not
v-CM) treated cells acquired a scattered, elongated
ﬁbroblast-like morphology, reminiscent of a mesenchy-
mal phenotype (Figure 2a, left vs right panels). Notably,
no or little induction of cell senescence was observed in
the p-CM-treated cell populations (Figure 2b). Next, we
found that p-CM treated cells were strongly vimentin-
positive (Figure 2c left vs right panel) and showed an
increased migratory capacity (Figure 2d, left and right
panels). QRT–PCR revealed high levels of ICAM1 and
ﬁbronectin mRNAs (Figure 2e), and a signiﬁcant
increase of vimentin, MMP-9 and of two EMT-
effectors, such as SNAIL and SLUG (Figure 2e). All
of the upregulated genes have been associated with the
acquisition of EMT and invasive properties in solid
malignancies (Ruco et al., 1996; Scarpa et al., 2002;
Sivertsen et al., 2006; Schramm et al., 2010; Casarsa
et al., 2011). p-CM treatment of other MPM cell lines
triggered similar changes (Supplementary Figure 2B).
Next, to test whether the p-CM-induced effects con-
tributed to the acquisition of tumorigenic properties
in vivo, we performed xenograft transplantation assays
(Figure 2f). Analysis of the clinical signs of the
xenografted mice revealed that mice transplanted with
p-CM-pretreated MSTO211H and NCI-H2052 cells
(1 week before transplantation) showed a higher frequency
and reduced latency of tumor development (Supplemen-
tary Figures 2C and D). This signiﬁcantly affected mice
survival (66.6% vs 16.7% residual survival for v-CM and
p-CM-treated MSTO211H cells, and 100% vs 33%
residual survival for v-CM and p-CM- treated NCI-
H2052 cells at day 115, respectively, Po0.05, Figure 2f).
These observations pair with the results of the in vitro
clonogenic assays (Figure 1b, lower panel).
p-CM-induced MPM cell subpopulations are enriched for
ALDHbright cells
In many solid tumors, the expression of high levels of
ALDH has been associated to the presence of tumori-
genic, invasive and chemoresistant cell subpopulations
(Adhikari et al., 2011). Interestingly, ﬂuorescence-
activated cell sorting (FACS) analysis revealed that the
EMT-like, p-CM- (and not v-CM) selected cell sub-
populations were highly enriched for ALDHbright cells
(Figure 3a). Notably, treatment with p-CM strongly
increased the number of ALDHbright cells in all the
analyzed MPM cell lines (Supplementary Figure 3A).
This suggests that soluble factors in the medium of the
pemetrexed-treated cells can modulate the number of
ALDHbright cells. Indeed, FACS analysis revealed that
some of the cytokines identiﬁed in the p-CM increased
the number of ALDHbright cells, with PlGF1, IL8, VEGF
and IFNg being the most effective in this regard
(Figure 3b). We also observed a degree of crosstalk
between the identiﬁed factors: for example, IL8, VEGF
and IFNg treatment increased the levels of
PlGF1mRNA (Supplementary Figure 3B) indicating
that p-CM contains cytokines acting as a complex
network.
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MPM ALDHbright cells exhibit TIC properties
To characterize the ALDHbright cell subpopulation
induced by p-CM, we FACS-sorted to purify ALDHbright
cells and ALDHlow cells from MSTO211H cells, and
evaluated their response to pemetrexed treatment
(Figures 3c and d). This showed that puriﬁed ALDHbright
cells were highly resistant to pemetrexed treatment
(Figure 3c) and highly clonogenic (Figure 3d), as
compared with ALDHlow cells. Migration assays
revealed that ALDHbright cells were capable to invade
matrigel much more efﬁciently than ALDHlow cells
(Figure 4e, left panel). In situ ALDH assay conﬁrmed
that most of the migrated cells were ALDHbright cells
(Figure 4e, right panel). This ﬁnding is relevant as we
found that puriﬁed ALDHbright cells rapidly divide by
generating both ALDHlow and ALDHbright cells, whereas
puriﬁed ALDHlow cells do not generate ALDHbright cells
(Supplementary Figure 4). Q–PCR analysis of freshly
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Figure 1 MPM cell lines undergo accelerated senescence upon pemetrexed treatment. (a) Dose–curve response of 3 MPM cell lines
and of a normal mesothelial cell line (HMC) to pemetrexed treatment (72 h). (b) CFA assay: Representative micrographs of colonies
formed by MSTO211H cells treated with pemetrexed as indicated for 6 h (upper panel) or 96 h (lower panel) before seeding. (c) SA-b-
Gal staining of MSTO211H cells treated with pemetrexed (20mM) for the indicated times. (d) Histograms showing the number of SA-b-
Gal-positive cells (right), of BrdU-positive nuclei (middle) and p21 mRNA levels (left) of cells treated as from C. (e) Q–PCR for the
expression of the indicated proinﬂammatory and mitogenic cytokines from either vehicle- and pemetrexed-treated cells (20mM, 96 h). (f)
ELISA quantiﬁcation of secreted cytokines from cells treated as in (e). Bars indicate the average of three independent experiments.
Statistics: Po0.05.
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puriﬁed MPM ALDHbright cells revealed higher mRNA
levels of MMP9 and of other two EMT factors, such as
SNAIL and SLUG (Figure 3f), which correlated with
the higher invasive ability of ALDHbright cells. We also
found very high mRNA levels of ABCG2, Nanog, Oct4,
Musashi and Sox2, with Nanog, Sox2 and OCT4 being
upregulated 470-folds in ALDHbright cells (Figure 3g).
Expression of the latter genes is associated with a poorly
differentiated, tumorigenic cell phenotype in many solid
malignancies (refer Discussion). Therefore, p-CM-in-
duced ALDHbright cells show both EMT-like and TIC
features.
Cell-autonomous signaling fuels expansion of ALDHbright
cells within pemetrexed-treated MPM cells
Next, we evaluated in greater detail the effect of
pemetrexed on puriﬁed ALDHbright cells (Figure 4). This
showed that ALDHbright cells undergo senescence to a
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Figure 2 CM from pemetrexed-treated MPM cells triggers EMT features. (a) Representative micrographs of MPM cells treated with
CM from pemetrexed-treated cells at the indicated times. (b) Histograms showing the number of SA-b-Gal-positive cells (right), of
BrdU-positive nuclei (middle) and p21 mRNA levels (left) of cells treated as from (a). (c) Indirect immunoﬂuorescence of MSTO211H
cells treated for 24 h with p-CM or v-CM. Red: vimentin. blue: DAPI staining. Scale bar: 100 mM. (d) Left panel: Representative
wound-healing closure assays of MSTO211H cells treated with p-CM or v-CM for 24 h. Right panel: Histogram showing the healing
closure efﬁciency of MSTO211H cells treated as from left panel at the indicated times. (e) Q–PCR for the expression of the indicated
EMT genes from cells treated as indicated for 24 h. Bars indicate the average of three independent experiments. Statistics: Po0.05. (f)
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much lesser extent than ALDHlow cells (26±4% vs
85±1.3 %, respectively, as revealed by SA-b-Gal
staining, Figure 4a). This was accompanied by a
concomitant increase in the number of ALDHbright cells
(Figure 4b), which did not take place for puriﬁed
ALDHlow cells. Interestingly, analysis of the cytokines
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expressed by pemetrexed-treated ALDHbright vs ALDHlow
cells revealed that the ALDHbright cells were endowed with
higher levels of IL6, IL8, and of IL6R, IL8R and Gp130
mRNAs (Figure 4c). In line with this, we found that
treatment of naive ALDHbright from MSTO211H cells with
CM from ALDHbright-treated cells increased dose-depen-
dently the number of ALDHbright cells (Figure 4d), and that
rIL6 and rIL8 had similar growth-promoting effects
(Figure 4e). This suggests that the increase in ALDHbright
cell number induced by pemetrexed treatment of MPM
cells may be mediated by IL6 and IL8 produced in a cell-
autonomous manner.
ALDHbright cells exist in vivo and survive pemetrexed
treatment
To assess whether the observed SASP-induced
ALDHbright cell subpopulations exist within primary
samples, we derived primary cells by mechanical and
enzymatic disaggregation of freshly excised human
surgical specimens (meso nos. 1, 2 and 4) or from
pleural effusions (meso nos. 3 and 5–9). FACS analysis
showed that a variable percentage of ALDHbright cells
could be readily identiﬁed in 9 out of 9 samples (Supple-
mentary Figure 5). We found that 9/9 MPM primary
cell cultures survived chronical pemetrexed treatment
(2 weeks–10 mM every 72 h) and 8/9 showed a time-
dependent increase of ALDHbright cells (Figure 5a), together
with a concomitant increase of SA-b-Gal-positive cells
(Figure 5b). Soft-agar CFA assays revealed that chronically
selected primary cultures were more clonogenic than those
exposed to vehicle alone (Figure 5c, inset).
SASP modulates MPM development in primary MPM
xenografts
We then investigated whether the increase of ALDHbright
cells in MPM primary cultures correlates with their
tumorigenicity in vivo. Quasi-orthotopic transplantation
assays with two primary cultures (meso nos. 4 and 5)
revealed that NOD/SCID mice transplanted with
pemetrexed-selected cells developed peritoneal mesothe-
lioma with higher efﬁciency (3/6 for meso no. 4 and
6/6 for meso no. 5 and at day 81 post-injection (p.i.),
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evaluation of ALDHbright cell number of puriﬁed cells treated as from (a). (c) Q–PCR mRNA expression levels of the indicated cytokine
and cytokine receptors expressed as a ratio of mRNA levels between ALDHbright and ALDHlow cells. (d, e) Dose–response curves of
freshly sorted ALDHbright cells to p-CM (d) and to recombinant IL6 and IL8 (e). Y-axis indicates the number of ALDHbright cells
evaluated by FACS. Error bars represent mean±s.d.
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respectively, Figure 5d) as compared with those
transplanted with vehicle-treated cells (0/6 for meso
no. 4 and 1/6 for meso no. 5 at day 81 p.i., respectively,
Figure 5d). Morphological analysis (H/E (hematoxylin
and eosin) and staining for human calretinin) of the
formalin-ﬁxed excised lesions conﬁrmed the human
nature of the material and the diagnosis of malignant
mesothelioma in all cases (Figure 5e). Notably, FACS
analysis of the excised tumors (when available) revealed
that the lesions generated by chronically treated MPMs
were signiﬁcantly enriched for ALDHbright cells
(13.5±2% vs 35±5% for meso no. 5 vs meso no. 5-
pemetrexed tumors, respectively, Figure 5d). Moreover,
we found that mRNA levels of ICAM1, Fibronectin,
Vimentin, as well as those of Oct4, Nanog and ABCG2
were higher in the more aggressive tumors (Figure 5f
upper and lower panel). We also found that intratumor-
al mRNA levels and the quantity of secreted IL8, PLGF
and VEGF-A into the peritoneal lavage ﬂuid of
mice were signiﬁcantly increased in mice transplanted
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with the more aggressive tumors (Figure 5g, upper and
lower panels). Altogether, these ﬁndings suggest that
many of the changes induced by p-CM in MPM cell
lines (Figures 1–3) occur in xenografted primary MPMs
as well.
RASV12–induced SASP modulates MPM ALDHbright cell
number
Expression of oncogenic RAS has been shown to induce
a strong SASP in untransformed ﬁbroblasts, and this
appears to be restrained by the p53 pathway (Coppe
et al., 2008). Therefore, to widen our observations
regarding the pemetrexed-induced SASP in MPM cells,
we tested whether expression of oncogenic RAS induces
similar changes into HMC cells, and whether alteration
of the p53 pathway could enhance the effect of RASv12.
In order to do this, we ﬁrst evaluated the status of p53 in
the HMC and MPM cell lines in our collection
(Supplementary Figure 6) Direct sequencing of p53
exons 5–8 showed that almost all of the cell lines are
endowed with wtp53 alleles, except for MMP-89 cells
that bear a deletion of both chromosomes 17 (Supple-
mentary Figure 6A). Moreover, cisplatin treatment
increased p53 levels and triggered nuclear accumulation
of p53 of representative cell lines (Supplementary
Figures 6B and C). Next, we retrovirally transduced
HMC cells with either control- or RASV12-expressing
vectors (pBABE and pBABE-RASv12, respectively) and
5 days later we performed RNA interference with either
scrambled- or p53-targeting small hairpin RNAs
(shRNAs) (Figure 6). We found that RASV12 expression
induced the appearance of ﬂat, enlarged SA-b-Gal-
positive cells in both scrambled- and shP53- transfected
cells within 8 days p.i. (Figures 6a and b). This paired
with a strong induction of IL6, IL8, IFNg and CXCL1
mRNAs, which were higher in RASv12-shP53 HMC cells
(Figure 6c). CM from both RASV12/scrambled cells and
RASv12/shp53 HMC cells strongly increased the number
of ALDHbright cells (Figure 6d), and the mRNA levels of
both EMT (SLUG, SNAIL and MMP9) and CSC (Oct4
and Nanog) markers (Figure 6e) on naive HMC cells.
We reproducibly observed a more marked effect of the
medium from RASv12/shp53 HMC cells (Figures 6c–e),
suggestive of an increased SASP. This suggests that
oncogenic RAS expression induces SASP-like changes
in MPM cells reminiscent of those elicited by peme-
trexed treatment.
STAT3 signaling is required for the SASP-induced
chemoresistance in vivo and in vitro
Some of the cytokines we identiﬁed in the p-CM or
induced by RASv12 expression are known to activate
STAT3 signaling (such as IL6 and IFNg) or to be
STAT3 target genes (such as VEGF, PLGF and IL8). In
line with this, we found that p-CM treatment of both
HMC and MPM cells induced a signiﬁcant increase of
STAT3 (Y705) phosphorylation in absence of changes in
the STAT3 protein levels (Figure 7a). In addition, p-CM
treatment promoted an increased nuclear accumulation
of p-STAT3 (Y705) (Figure 7b). To assess the relevance
of STAT3 phosphorylation for the p-CM-induced
effects, we generated MPM cell lines stably knocked
down for STAT3 (Figure 7c). We found that STAT3
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knockdown strongly affected the resistance of
MSTO211H and NCI-H2052 to pemetrexed treatment,
as revealed by both viability and clonogenic assays (as
compared with cells transduced with scrambled shRNA,
Figures 7d and e, respectively). Moreover, we found that
the number of ALDHbright cells in the STAT3 k/d cells was
deeply reduced both in basal conditions (v-CM) and upon
p-CM treatment (Figure 7f). Finally, we found that
induction of some EMT genes by p-CM was strongly
reduced as well (Figure 7g). To investigate whether
STAT3 activation has a role in mediating SASP-induced
effects in vivo, we performed xenograft assays with either
scrambled- or -STAT3 k/d MSTO211H (scrambled and
shSTAT3, respectively). We started pemetrexed treatment
(i.p injection every 3 days at 100mg/kg, Figure 7h,
arrows) when the engrafted tumors were X0.1 cm3 in
volume (day 1, Figure 7h). First, we observed that among
the vehicle-treated mice, the tumors formed by STAT3 k/
d cells were smaller as compared with the ones formed by
control cells (Figure 7h). In addition, we found that all the
engrafted tumors were sensitive to pemetrexed treatment
(Figure 7h), with the tumors from STAT3 k/d cells being
the most sensitive ones. Indeed, a prolonged inhibition of
tumor growth was observed in mice carrying STAT3 k/d
tumors and treated with the antifolate (Figure 7h,
Po0.05). We obtained similar results with STAT3 k/d
NCI-H2052 cells (data not shown). Interestingly, FACS
analysis of representative excised tumors (n¼ 4) revealed
that the tumors formed by STAT3 k/d cells were endowed
with much lower number of ALDHbright cells, thus pairing
our in vitro observations (Figure 7f).
Discussion
The work presented on this paper investigates mesothe-
lioma chemoresistance, a major feature of MPM, which
strongly inﬂuences the history of the disease. We show
here, for the ﬁrst time, that pemetrexed treatment of
mesothelioma cell lines and primary MPM cells readily
induces a senescent phenotype with features of SASP
(Coppe et al., 2010) (Figure 1). SASP consists of
premature senescence and secretion of a complex mix
of cytokines, chemokines and growth factors (Laberge
et al., 2011). We show that treatment of naive MPM
cells with CM derived from pemetrexed-treated MPM
cells promotes the emergence of mesenchymal-like,
chemoresistant cell subpopulations endowed with high
levels of ALDH activity (ALDHbright cells). ALDHbright
cells are a minor fraction of unfractionated MPM cell
populations. However, puriﬁed ALDHbright cells (as
compared with ALDHlow cells) show prominent tumori-
genic properties in vitro, and their number correlates
with frequency and latency of mesothelioma develop-
ment in NOD/SCID mice (Figures 2 and 5). In addition,
puriﬁed ALDHbright cells rapidly generate ALDHlow cells
and reconstitute the composition of the originating
culture, according to a ‘progenitor-like’ status (Supple-
mentary Figure 4). ALDHlow cells, in turn, produce
cytokines that promote expansion of ALDHbright cells
(Figures 3b and 4c). Therefore, both ALDHlow and
ALDHbright cell subpopulations may closely cooperate in
determining the transformed MPM phenotype through
cell-autonomous as well as non-autonomous mechan-
isms (Figure 8, model). EMT-like cells with high ALDH
activity and tumorigenic features have been described in
many solid and non-solid tumors (Charafe-Jauffret
et al., 2010; Cioce et al., 2010; Kryczek et al., 2011;
Ma and Allan, 2011; Marcato et al., 2011; Wang et al.,
2011). In addition, it has been recently shown that the
expansion of breast ALDHbright cells is sustained by
mesenchymal bone marrow-derived cells. This is
mediated by IL-8 (Liu et al., 2011). Mesothelial cells
acquire mesenchymal features in response to a variety of
inﬂammatory conditions (Park et al., 2003; Aroeira
et al., 2007; Kim et al., 2011). It is tempting to speculate
whether mesothelial cells may functionally substitute the
bone marrow-derived cells described by Liu et al. (2011)
during the inﬂammation-driven progression of MPM.
This is the ﬁrst time, to our knowledge, that a direct link
between SASP and chemoresistance has been addressed.
Interestingly, this is signiﬁcant in regards to the inverse
relationship between expression of senescence markers
and patient survival observed by Sidi et al. (2011) in
chemo-treated primary MPMs. Thus, the presence of
senescent MPM cells within growing tumours seems to
be required for tumour survival. Our in vivo studies do
not demonstrate that ALDHbright cells are responsible for
MPM development. However, the pro-tumorigenic
behaviour demonstrated by ALDHbright cells in vitro
and in vivo calls for future studies to be conducted on a
larger cohort of patients. An increase of ALDHbright cells
(for example, in the pleural exudate of patients) could be
of diagnostic or prognostic value in staging MPM.
We attempted to explain SASP-mediated signaling in
pemetrexed-treated cells in more detail. We identiﬁed
STAT3 activation as a crucial event downstream to
SASP-induced cytokine signaling in MPM cells. STAT3
is a possible prerequisite for the modulation of EMT
genes by SASP-induced cytokines, and is important to
maintain the ALDHbright cell pool (Figure 7). In fact,
shRNA-mediated depletion of STAT3 potentiates the
effect of pemetrexed in vivo (Figure 7). The relevance of
STAT3 signaling for MPM cells is reinforced by the
observation that most SASP cytokines identiﬁed here
are either STAT3 activators (IL6 and IFNg) or known
Figure 6 RASv12 expression induces SASP and increases MPM ALDHbright cell number. (a) SA-b-Gal staining of HMC cells
retrovirally transduced with the indicated expression vectors. (b) Histograms showing the number of SA-b-Gal-positive cells as from
(a). (c) QRT–PCR. mRNAlevels of the indicated proinﬂammatory and mitogenic cytokines from cells transduced as indicated.
(d) Upper panel: In situ ALDH assay of HMC cells trasduced as indicated. Lower panel: FACS-based analysis of ALDHbright cells in
HMC cells as from A. (e) QRT–PCR. Fold changes in mRNA expression levels of the indicated TIC/EMT genes of naive HMC cells
treated with CM from the indicated cells. Bars indicate the average of three independent experiments.
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Figure 7 STAT3 is required for SASP-induced chemoresistance in vivo and in vitro. (a) Representative western blot analysis of whole
cell lysates obtained from HMC and MSTO211H cells treated with p-CM for 30min. Upper panel: Anti-pSTAT3 (Y705) staining.
Middle panel: anti-STAT3 antibody. Lower panel: Loading control (anti-tubulin staining). (b) Indirect immunoﬂuorescence of
MSTO211H cells treated for 30min with p-CM or v-CM. Red: pSTAT3 (y705). Blue: DAPI staining. Scale bar: 30 mm. (c)
Representative western blot analysis of whole cell lysates obtained from MSTO211H cells transduced with either scrambled- or
STAT3-shRNA-targeting vectors and treated with p-CM for 30min. Upper panel: Anti p-STAT3 (Y705) staining. Middle panel: Anti-
STAT3 antibody. Lower panel: Loading control (anti-tubulin staining). (d) Dose–response curves of MSTO211H cells as from C to
pemetrexed treatment. (e) Histograms showing average colony counts of scrambled- and shSTAT3 MSTO211H cells treated with v-
CM and p-CM. (f) Histogram showing the percentage of ALDHbright cells in scrambled- and shSTAT3-transduced MSTO211H cells
treated as from 7E. (g) Q–PCR. Fold changes in mRNA expression levels of the indicated EMT genes from scrambled- and shSTAT3-
transduced MSTO211H cells treated as indicated. Error bars represent mean±s.d. (h) Tumor volume of xenografted tumors from
scrambled- and shSTAT3-transduced MSTO211H cells treated i.p. with pemetrexed (100mg/kg per 3 days, n¼ 4) when the tumor
volume was X0.1 cm3. Po0.05; asterisks (*) indicate no statistically signiﬁcant differences between the samples.
(i) Histograms showing the percentage of ALDHbright cells from representative excised tumors (n¼ 4) as from 5H. Statistics: Po0.05.
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STAT3 target genes (IL8, PLGF and VEGF) (Takeda
and Akira, 2000; Schindler et al., 2007; Oka et al., 2010;
Huang et al., 2011a,b). Notably, some of them are
prognostically relevant for MPM in vivo, such as
PLGF1 (Albonici et al., 2009; Pompeo et al., 2009).
Additionally, nuclear positivity for pSTAT3 has been
described in 60% of malignant mesothelioma cases
(Achcar Rde et al., 2007).
Our data suggest that the involvement of p53 pathway
in MPM, typically considered as a wtp53-carrying
tumor (Metcalf et al., 1992; Mor et al., 1997), must be
further investigated. We show that RNAi-mediated
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downregulation of p53 strongly affects the magnitude of
SASP in HMC cells infected with RASv12 (Figure 6).
Despite our data being obtained by artiﬁcially manip-
ulating the levels of p53 in wtP53-HMC and -MPM cells
(Supplementary Figure 6), evidence that downstream
p53 signaling may be altered in MPM is accumulating.
It is worthy to note that downregulation of mir-34 b/c
(by promoter methylation) in MPM cells has been
recently described by Kubo et al. (2011). Mir-34b/c are
direct transcriptional targets of p53 and part of the p53
tumor suppressor network (He et al., 2007; Hermeking,
2007). In addition, some of the deregulated targets of
mir-34 b/c may be involved in SASP signaling, such as c-
Met (Corney et al., 2007), which is the HGF ligand. The
MET/HGF axis is frequently altered in MPM (Tolnay
et al., 1998). We suggest that the strong tendency of
mesothelial cells undergoing EMT upon inﬂammatory
stimuli (such as asbestos exposure) and functional
alterations of the p53 pathway (with consequent
deregulation of possible SASP effectors) may favor the
emergence of SASP-induced chemoresistant cell sub-
populations in MPM. We observed that SASP-induced
tumorigenic properties (EMT, chemoresistance, acquisi-
tion of migratory/invasive properties and progenitor-
like features) appear to be mediated by distinct sets of
cytokines with partially overlapping functions. This may
explain the limited therapeutic efﬁcacy of single
cytokine-targeting agents in MPM observed to date
(Li et al., 2007; Bais et al., 2010; Suzuki et al., 2010; Yao
et al., 2011). Therefore, we believe that interference with
STAT3 signaling (a broad modulator of SASP-induced
effects) may be a promising strategy in counteracting
MPM chemoresistance.
Materials and methods
Cell lines and culture conditions
The human MPM cell lines MSTO211H, NCI-H28, NCI-
H2052 and NCI-H2452 were obtained from the ATCC
(Rockville, MD, USA). MPP-89 cells were obtained from the
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
HMC cells were from Tebu-Bio, Le Perray en Yvelines,
France. All the cell lines were cultured as monolayers at 37 1C
and 5% CO2 in DMEM/F12þGLUTAMAX (Invitrogen-
Gibco, Carlsbad, CA, USA) supplemented with 10% non-heat
inactivated FBS (fetal bovine serum) (Invitrogen-Gibco) and
5 mg/ml insulin (Sigma-Aldrich, St Louis, MO, USA). Before
treatment with CM or recombinant cytokines, cells were
shortly (6 h) cultured in starvation medium DMEM/
F12þGLUTAMAX supplemented with 1% BSA-FAF
(fatty acid-free bovine serum albumin) and 5 mg/ml insulin
(Sigma-Aldrich).
Primary MPM cultures
Primary MPM cultures (meso nos 1, 2 and 4) were generated
as follows: brieﬂy, solid tissues were manually minced and
subjected to collagenase/ialuronidase digestion (300U/100U,
respectively) for 2 h in digestion medium (DMEM/
F12þGLUTAMAX supplemented with 1% BSA-FAF and
5 mg/ml insulin). Digested material was then ﬁltered through a
nylon mesh (70 mm), collected by gentle centrifugation and
resuspended in fresh medium DMEM/F12þGLUTAMAX
(1:1, Invitrogen, Carlsbad, CA, USA) supplemented with 5%
non-heat inactivated FBS, insulin 10mg/ml and ciproﬂoxacin
(4 mg/ml). Pleural effusions (meso nos 3, 5 and 9) were
centrifuged for 10min at 1000 r.p.m. before being treated as
primary MPMs.
ALDH activity assay and cell sorting
ALDH activity was detected in situ by using a ﬂuorescence
microscope or by FACS analysis (Guava easyCyte, Millipore,
Billerica, MA, USA). ALDEFLUOR kit (Stem Cell Technol-
ogies, Vancouver, Canada) was used in both cases, according
to the manufacturer’s instructions. Sorting of MPM cell
subpopulations was performed by using a MoFlo FACS
instrument (DAKOCytomation, Carpinteria, CA, USA)
equipped with a refrigerated chamber. ALDH-positive cells
were deﬁned as the cells that displayed greater ﬂuorescence
compared with a control staining reaction containing the
ALDH inhibitor, DEAB (diethylaminobenzaldehyde).
Cell viability assay
Cell viability of treated cells was assessed by ATPlite assay
(Perkin Elmer, Boston, MA, USA) according to manufac-
turer’s instructions.
Reagents and cytokines
Pemetrexed (Eli Lilly and Company, Indianapolis, IN, USA),
Cisplatin (Sigma-Aldrich), IL6 and IL8 (ORF Genetics, Kopavo-
gur, Iceland); VEGF (BD Biosciences Pharmingen, San Diego,
CA, USA); PLGF1 (ProspectBio, Rehovot, Israel); IFNg (Milli-
pore, Billerica, MA, USA) and CXCL1 (R&D,Minneapolis, MN,
USA) were all dissolved according to manufacturer’s instructions.
SA-b-Gal staining
SA-b-galactosidase staining was performed on adherent cells
according to published protocols (Debacq-Chainiaux et al.,
2009).
Cytokine quantiﬁcation
Levels of secreted IL6, IL8, IFNg and VEGF from CM or
peritoneal washing ﬂuid of mice were quantitated by Human
Singleplex Bead Kit (Invitrogen). Quantikine Immunoassay
(R&D) was used to quantify CXCL1 and PlGF1 levels,
respectively.
BrdU incorporation assay
Detection of BrdU incorporation was performed by ELISA
(BrdU Cell Proliferation Assay Kit, Cell Signaling Techno-
logy, Danvers, MA, USA) according to the manufacturer’s
instructions.
Wound healing assay
Cells grown to 95% conﬂuence were seeded in 6-well tissue
culture plates and wounded with a sterile 10-ml pipette tip to
remove cells. Digital micrographs were taken after scratching
and at the indicated times.
Invasion assay
Matrigel invasion assays were performed as follows: Brieﬂy,
20mg per well of Matrigel (BD Biosciences) were applied to
24-well transwell plates with 8m pore size (BD Biosciences) and
allowed to solidify overnight. 30000 cells resuspended in fresh
medium were seeded into each well. The plates were incubated at
37 1C for 72h, and then cells at the bottom were ﬁxed and stained.
Transmigrated cells were normalized for initial number of seeded
live cells or subjected to in situ ALDH assay, as indicated before.
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Clonogenic assay
MPM cells were seeded at 100 (ALDHbright)-5000 (bulk) cells
per 6-well dish. Formed colonies were stained with crystal
violet 10–15 days later. When indicated, cells were resuspended
in 0.3% methylcellulose before plating.
Q–PCR
Total RNA was extracted using the Trizol Reagent (Gibco).
The ﬁrst-strand cDNA was synthesized according to manu-
facturer’s instructions (M-MLV RT kit, Invitrogen). Gene
expression was measured by real-time PCR using the Sybr-
Green assay (Cell Signaling Technology) on a 7900HT
instrument (Applied Biosystems). Q–PCR primers are reported
in Supplementary Table 1.
Xenograft transplantation
Suspensions of 1 106 MSTO211H cells were injected i.p.
(Figure 1) or s.c. (Figure 7) in PBS1X/Matrigel (BD
Biosciences) into 5-weeks-old male CD1 mice (Charles River,
Milan). Body weight and clinical signs of the mice were
determined every 3 days, and in case of i.p. transplantation,
mesothelioma development was suggested by the presence of
42 g per week variation of body weight, worsening of clinical
symptoms and appearance of ascitic ﬂuid. For s.c. transplanta-
tion, tumor volume was calculated using the formula: V¼ p/6
 lengthwidth (by manual caliper). Mice were treated i.p. with
pemetrexed (100mg/kg per 3 days, n¼ 4) when the tumor volume
was X0.1 cm3. All tumorigenicity assays were carried out
according to the guidelines set by the Internal Ethical Committee.
MPM transplantation in NOD/SCID mice
Suspensions of 0.5 106 human primary MPM cultures were
injected i.p. in PBS1X/Matrigel (BD Biosciences) into 5-weeks-
old male NOD/SCID mice (Charles River Laboratories,
Calco, LC, Italy). Body weight and clinical signs of the mice
were determined as described before. Diagnosis of malignant
mesothelioma was conﬁrmed by expert pathologists (H/E and
anti-human calretinin staining (Ventana Medical Systems, Oro
Valley, AZ, USA) of nine representative sections of each
excised lesion).
Western blot
For Western blotting, the following antibodies were used: anti-
pSTAT3 (Tyr-705) (#sc-8059), anti-STAT3 (#sc-7179), anti-
Tubulin (#sc-23948) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-p53 (DO-1, Calbiochem, San Diego, CA,
USA).
Immunoﬂuorescence microscopy
Brieﬂy, cells were ﬁxed/permeabilized in paraformaldehyde/
methanol, aspeciﬁc binding blocked in PBS containing 1%
bovine serum albumin, and labeled with anti-Vimentin anti-
body (VIM-13.2 Sigma, 1:100 dilution), p-STAT3 (Tyr-705)
(#sc-8059) or p53 (pantropic DO-1, Calbiochem). The
secondary antibody was an Alexa 488-conjugated goat anti-
mouse IgG (Calbiochem). Nuclei were visualized by 40,6-
diamidino-2-phenylindole (DAPI) staining.
Retroviral transduction of HMC and MPM cells
The pBabe, pBabe-RasV12, pRETRO SUPER p53, pRETRO,
pSIH1-puro-STAT3 shRNA and pSIH1-puro-scrambled-
shRNA (plasmids 26596 and 26597, Addgene, Cambridge, MA,
USA) constructs were transfected into the 293T packaging cells
(Invitrogen) by Ca-PO4 precipitation method. Virus-containing
supernatants were used to infect MPM or HMC cells (three cycles
of infection). Cells were selected by puromycin (1mg/ml every 48h
for 1 week).
Figure 8 Schematic working model. SASP triggers EMT and TIC features in MPM by cell-autonomous and cell-non-autonomous
mechanisms.
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Statistical analysis
Student’s t-test was used to assess signiﬁcance of the in vitro
data, whereas the signiﬁcance of mice survival data was
determined by using Kaplan-Meier analysis and Log Rank test
for statistical signiﬁcance. P values of p0.05 were considered
statistically signiﬁcant. When indicated, asterisks indicate no
statistically signiﬁcant differences between the labeled samples.
Abbreviations
EMT, epithelial-to-mesenchymal–transition; MPE, mesothelial
peritoneal exudate; SASP, senescence-associated-secretory-pheno-
type; TICs, tumor-initiating–cells.
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